fenoldopam
Trade name: corlopam
Approved
Sep 23, 1997
Fenoldopam (marketed under the brand name Corlopam) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. Fenoldopam Mesylate Injection, USP is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. — NCATS
Clinical trial activity
13 trials · 18 clinical orgs · 8 marketing orgs
Earliest trial started May 1, 2002 (NCT00122018)
Timeline
1990s
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
- Dec 1, 2003
Lutipold — Marketing Organization
- Dec 1, 2003
Sankyo — Marketing Organization
- Oct 12, 2004
West-Ward Pharmaceutical — Marketing Organization
- Oct 12, 2004
Hikma — Marketing Organization
- Feb 15, 2005
Sandoz — Marketing Organization
- Feb 15, 2005
Novartis — Marketing Organization
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
- Mar 7, 2007
Teva — Marketing Organization
- Jan 1, 2008
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Dopamine D1 receptorAGONIST
DRD1 agonist
Approval history
- approvedSep 23, 1997
Chemistry & pharmacology
SMILES
Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1- Mol. weight
- 305.76 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL588 ↗
- WikipediaFenoldopam ↗
- NCATSINU8H2KAWG ↗
- ChEMBLCHEMBL1026 ↗
Also known as
- corlopam
- corlopam
- corlopam
- corlopam
- fenoldopam
- fenoldopam
- fenoldopam
- fenoldopam
- fenoldopam
- fenoldopam
- fenoldopam
- fenoldopam
- fénoldopam
- fénoldopam
- fenoldopam hydrobromide
- fenoldopam hydrobromide
- fenoldopam hydrobromide
- fenoldopam hydrobromide
- fenoldopam hydrobromide
- fenoldopam hydrobromide
- fenoldopam mesilate
- fenoldopam mesylate
- fenoldopam mesylate
- fenoldopam mesylate
- fenoldopam mesylate
- fenoldopamum
- fenoldopamum
- sk-82526
- sk-82526
- sk-82526-j
- sk-82526-j
- sk&f-82526
- sk&f-82526
- sk&f-82526j
- sk&f-82526j
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02620761 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2017 | Medical College of Wisconsin, University of Iowa |
| NCT01690832 | Phase 4 | Sep 1, 2012 | University of Roma La Sapienza |
| NCT01073189 | Phase 4 | Apr 1, 2010 | Southeast Renal Research Institute |
| NCT00982527 | Phase 3 | Sep 1, 2009 | Bambino Gesù Hospital and Research Institute |
| NCT00747331 | Phase 4 | Sep 1, 2008 | University of Milan |
| NCT00286403 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2008 | Dialysis Clinic, Inc., Emory University, Southeast Renal Research Institute |
| NCT00557219 | Phase 3 | Apr 1, 2008 | Medical University of Gdansk |
| NCT00621790 | Phase 3 | Feb 1, 2008 | Vita-Salute University of Milano. Italy |
| NCT00592150 | Phase 1 | Jun 1, 2007 | National Institutes of Health (NIH), University of Virginia |
| NCT00467181 | Phase 2 | Jan 1, 2005 | Summa Health System |
| NCT01324245 | N/A | Nov 1, 2002 | Georgetown University, University of Virginia |
| NCT00743106 | N/A | Sep 1, 2002 | University of Rochester |
| NCT00122018 | Phase 2 | May 1, 2002 | Abbott, Pulmonary and Critical Care Assoc. of Baltimore, Pulmonary Critical Care Associates of Baltimore |
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Southeast Renal Research Institute | Academic/Hospital | 2 | 2 | 2 | 2008 |
| University of Virginia | Academic/Hospital | 2 | 1 | 2 | 2002 |
| Abbott | For profit | 1 | 0 | 1 | 2002 |
| Bambino Gesù Hospital and Research Institute | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Dialysis Clinic, Inc. | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Medical University of Gdansk | Academic/Hospital | 1 | 1 | 1 | 2008 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2007 |
| Pulmonary and Critical Care Assoc. of Baltimore | Academic/Hospital | 1 | 0 | 1 | 2002 |
| Pulmonary Critical Care Associates of Baltimore | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Summa Health System | Academic/Hospital | 1 | 1 | 1 | 2005 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Milan | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2002 |
| University of Roma La Sapienza | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 1 | 1 | 2008 |
Marketing (11)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Hikma | For profit | SYN | Oct 12, 2004 |
| Hikma | For profit | MKTG | Oct 12, 2004 |
| Hospira | For profit | NDA2 | Sep 23, 1997 |
| Hospira | For profit | NDA | Sep 23, 1997 |
| Lutipold | For profit | MKTG | Dec 1, 2003 |
| Novartis | For profit | MKTG | Feb 15, 2005 |
| Sandoz | For profit | MKTG | Feb 15, 2005 |
| Sandoz | For profit | SYN | Feb 15, 2005 |
| Sankyo | For profit | MKTG | Dec 1, 2003 |
| Teva | For profit | MKTG | Mar 7, 2007 |
| West-Ward Pharmaceutical | For profit | MKTG | Oct 12, 2004 |